Oslo, 29 April 2022 - Observe Medical ASA ("the Company" or "Observe Medical")
today announces that the Company has published its Annual Report for 2021, which
was approved by the board of directors on 28 April 2022.
"It has been a transformational start to 2022, so I would like to take this
opportunity to focus on the way forward. We have a strong portfolio of
proprietary medtech products available globally, an international and dedicated
team, and the drive to succeed. We have an exciting road ahead, and I look
forward to embarking on this journey alongside our dedicated and highly valued
team," commented Rune Nystad, CEO of Observe Medical.
The Annual Report for 2021 is attached to this notice and is available on the
company's website, www.observemedical.com, under Investor Relations.
For further information, please contact:
Rune Nystad, CEO Observe Medical
Mobile: +47 916 24 683
Per Arne Nygård, CFO of Observe Medical
Mobile: +47 411 04 345
About Observe Medical
Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.
The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement, anesthesiology/ICUs, surgery and wound care, in
combination with targeted M&A.
The Company is headquartered in Oslo, Norway, with additional offices in Narvik,
Norway and Gothenburg, Sweden, and subsidiaries in Finland and the US. In
addition, Observe Medical has a direct sale organization in the Nordics and a
distributor network internationally.
Further information is available at www.observemedical.com.